Business Wire

Everbridge Appoints World-renowned Technologist, and “One of the Most Influential People of the 21st Century,” as Chief Customer Experience Officer to Innovate the Next Generation of Critical Event Management (CEM)

12.10.2020 14:30:00 EEST | Business Wire | Press release

Share

Everbridge, Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM), today announced the appointment of Dr. John Maeda to the new role of Chief Customer Experience Officer. As a renowned technologist and designer, Dr. Maeda will help innovate the next generation of critical event management for every stakeholder in a world where safety and resiliency standards are forever changed by the coronavirus pandemic. Recognized as one of the “75 Most Influential People of the 21st Century” by Esquire, Dr. Maeda brings unmatched credentials to Everbridge as an MIT-trained engineer and researcher, public company board member and C-Level executive, Silicon Valley venture capital partner, digital transformation thought leader and acclaimed TED-talk presenter who combines world-class technology and design expertise with a passion for diversity, equity, and inclusion.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201012005215/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Everbridge Appoints World-renowned Technologist, and “One of the Most Influential People of the 21st Century,” as Chief Customer Experience Officer to Innovate the Next Generation of Critical Event Management (CEM) (Photo: Business Wire)

Serving a powerful mission to keep people safe and organizations running, Everbridge was founded in the aftermath of 9/11, helping organizations manage major threats for close to 20 years since. As the pioneer of critical event management, Everbridge, and its mission, now grow in importance every day as the world navigates a generational ‘black swan’ event resulting from coronavirus. Impacting nearly every individual on the planet, COVID-19 dramatically changes how government leaders, CEOs and boards of companies, citizens, employees, public health workers, and front line emergency responders, must prepare for a variety of critical events that can impact people, operations, supply chain and brand.

“As COVID-19 remains a pervasive and persistent threat further compounded by other critical events such as hurricanes, wildfires, and cyberattacks, the importance of critical event management to all individuals and organizations continues to increase,” said David Meredith, CEO of Everbridge. “As the pioneer and leader in Critical Event Management, Everbridge continues to elevate the experience for stakeholders at each touch point with our technology.”

Continued Meredith, “Our mission, market-leading technology, and leadership position in an increasingly relevant and critical sector, enables us to attract the very best talent to Everbridge which Dr. John Maeda represents. John’s innovative approach to digital transformation and design will be instrumental as Everbridge optimizes the experience for individuals, organizations and governments to meet the challenges and risks of an uncertain world.”

“The stakes of managing critical events well, and more proactively, have never been higher, as typified by the coronavirus,” said Dr. John Maeda. “I’m very excited to apply my experience digitally transforming how organizations communicate and solve business problems to this incredibly important area. Everbridge, as the category creator and clear leader in critical event management, offers the platform where I can have the most impact in helping to save lives and livelihoods, a truly fulfilling mission.”

Prior to Everbridge, Dr. Maeda served as Chief Experience Officer at $11+B revenue communications and technology firm Publicis where he led their CX/DX practices to be recognized by Forrester and Gartner as Leaders. Maeda serves on the Boards of Sonos Inc. and the Cooper Hewitt Smithsonian Design Museum. He held leadership positions with Automattic, the parent company of WordPress.com and formerly the world’s largest all-distributed tech company; advertising agency Wieden + Kennedy; and the venture capital firm Kleiner Perkins; worked as an advisor to Google and eBay; served as president of the Rhode Island School of Design; and began his early career at MIT at the intersection of computer science and visual design.

Maeda authored several celebrated books including How To Speak Machine, The Laws of Simplicity, and Redesigning Leadership. He appeared as a speaker all over the world, from Davos to Beijing to São Paulo to New York, his talks for TED received millions of views, and Maeda’s Twitter feed was named one of the 140 best by TIME Magazine.

Maeda received the White House’s National Design Award, the Tribeca Film Festival’s Clayton Christensen Disruptive Innovation Award for STEM to STEAM, the Blouin Foundation’s Creative Leadership Award, the AIGA Medal, the Raymond Loewy Foundation Prize, the Mainichi Design Prize, the Tokyo Type Director’s Club Prize, and induction into the Art Director’s Club Hall of Fame.

Maeda holds BS and MS degrees in Electrical Engineering and Computer Science from Massachusetts Institute of Technology (MIT), an MBA from Arizona State University, a PhD from University of Tsukuba in Japan, and honorary doctorate degrees from Drexel University, Simon Fraser University, and Maryland Institute College of Art.

Dr. Maeda will join keynote speakers this week including a former World Head of State, as well as the Director of the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health (NIH) Dr. Anthony Fauci, Virgin Group Founder Sir Richard Branson, and renowned neurosurgeon and CNN Chief Medical Correspondent Dr. Sanjay Gupta, at Everbridge’s “COVID-19 R2R: The Road to Recovery” virtual leadership summit. To learn more, please visit Everbridge’s event registration page.

About Everbridge

Everbridge, Inc. (NASDAQ: EVBG) is a global software company that provides enterprise software applications that automate and accelerate organizations’ operational response to critical events in order to Keep People Safe and Businesses Running™. During public safety threats such as active shooter situations, terrorist attacks or severe weather conditions, as well as critical business events including IT outages, cyber-attacks or other incidents such as product recalls or supply-chain interruptions, over 5,300 global customers rely on the company’s Critical Event Management Platform to quickly and reliably aggregate and assess threat data, locate people at risk and responders able to assist, automate the execution of pre-defined communications processes through the secure delivery to over 100 different communication devices, and track progress on executing response plans. The company’s platform sent over 3.5 billion messages in 2019 and offers the ability to reach over 600 million people in more than 200 countries and territories, including the entire mobile populations on a country-wide scale in Australia, Greece, Iceland, the Netherlands, New Zealand, Peru, Singapore, Sweden, and a number of the largest states in India. The company’s critical communications and enterprise safety applications include Mass Notification, Incident Management, Safety Connection™, IT Alerting, Visual Command Center®, Public Warning, Crisis Management, Community Engagement™ and Secure Messaging. Everbridge serves 8 of the 10 largest U.S. cities, 9 of the 10 largest U.S.-based investment banks, 47 of the 50 busiest North American airports, 9 of the 10 largest global consulting firms, 8 of the 10 largest global auto makers, all 4 of the largest global accounting firms, 9 of the 10 largest U.S.-based health care providers, and 7 of the 10 largest technology companies in the world. Everbridge is based in Boston and Los Angeles with additional offices in Lansing, San Francisco, Abu Dhabi, Beijing, Bangalore, Kolkata, London, Munich, New York, Oslo, Singapore, Stockholm and Tilburg. For more information, visit www.everbridge.com, read the company blog, and follow on LinkedIn, Twitter, and Facebook.

Cautionary Language Concerning Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the anticipated opportunity and trends for growth in our critical communications and enterprise safety applications and our overall business, our market opportunity, our expectations regarding sales of our products, our goal to maintain market leadership and extend the markets in which we compete for customers, and anticipated impact on financial results. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as “expect,” “anticipate,” “should,” “believe,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “could,” “intend,” variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control. Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the ability of our products and services to perform as intended and meet our customers’ expectations; our ability to successfully integrate businesses and assets that we may acquire; our ability to attract new customers and retain and increase sales to existing customers; our ability to increase sales of our Mass Notification application and/or ability to increase sales of our other applications; developments in the market for targeted and contextually relevant critical communications or the associated regulatory environment; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we have not been profitable on a consistent basis historically and may not achieve or maintain profitability in the future; the lengthy and unpredictable sales cycles for new customers; nature of our business exposes us to inherent liability risks; our ability to attract, integrate and retain qualified personnel; our ability to maintain successful relationships with our channel partners and technology partners; our ability to manage our growth effectively; our ability to respond to competitive pressures; potential liability related to privacy and security of personally identifiable information; our ability to protect our intellectual property rights, and the other risks detailed in our risk factors discussed in filings with the U.S. Securities and Exchange Commission (“SEC”), including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on February 28, 2020. The forward-looking statements included in this press release represent our views as of the date of this press release. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

All Everbridge products are trademarks of Everbridge, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Everbridge Contacts:
Jeff Young
Media Relations
jeff.young@everbridge.com
781-859-4116

Joshua Young
Investor Relations
joshua.young@everbridge.com
781-236-3695

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye